INS018_055 for Idiopathic Pulmonary Fibrosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new oral medication, INS018_055, in adults with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medication is safe and well-tolerated over a few months.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it allows participants who are already on stable doses of pirfenidone or nintedanib for more than 8 weeks to join. It seems you can continue these medications if they are stable.
Are You a Good Fit for This Trial?
Adults over 40 with Idiopathic Pulmonary Fibrosis (IPF) who meet specific lung function criteria can join this trial. They must have a stable condition and not have had an acute IPF exacerbation in the last 4 months. Smokers or those unwilling to quit, pregnant or nursing women are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive INS018_055 or placebo orally for up to 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- INS018_055
INS018_055 is already approved in United States, China for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
InSilico Medicine Hong Kong Limited
Lead Sponsor